BR9909872A - uso de dexmedetomidina para uma unidade de sedação de proteção intensiva - Google Patents
uso de dexmedetomidina para uma unidade de sedação de proteção intensivaInfo
- Publication number
- BR9909872A BR9909872A BRPI9909872-5A BR9909872A BR9909872A BR 9909872 A BR9909872 A BR 9909872A BR 9909872 A BR9909872 A BR 9909872A BR 9909872 A BR9909872 A BR 9909872A
- Authority
- BR
- Brazil
- Prior art keywords
- dexmedetomidine
- patient
- unit
- intensive
- intensive protection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
USO DE DEXMEDETOMIDINA PARA UMA UNIDADE DE SEDAçãO DE PROTEçãO INTENSIVA. A presente invenção relata um método de sedar um paciente em uma unidade de proteção intensiva (ICU). O método compreende a administração de dexmedetomidina ou seu sal farmaceuticamente aceitável em um paciente que precisa dela por um período suficiente de tempo. Adicionalmente, a presente invenção relata um método de sedar um paciente em ICU pela administração de dexmedetomidina ou seu sal farmaceuticamente aceitável, onde a dexmedetomidina é essencialmente o único agente ativo ou o único agente ativo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8028798P | 1998-04-01 | 1998-04-01 | |
US11094498P | 1998-12-04 | 1998-12-04 | |
PCT/FI1999/000266 WO1999049854A2 (en) | 1998-04-01 | 1999-03-31 | Use of dexmedetomidine for icu sedation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9909872A true BR9909872A (pt) | 2007-11-20 |
Family
ID=26763325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI9909872-5A BR9909872A (pt) | 1998-04-01 | 1999-03-31 | uso de dexmedetomidina para uma unidade de sedação de proteção intensiva |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1069893B1 (pt) |
JP (1) | JP4606581B2 (pt) |
KR (1) | KR20010034728A (pt) |
CN (1) | CN1168441C (pt) |
AR (1) | AR015744A1 (pt) |
AT (1) | ATE347359T1 (pt) |
AU (1) | AU754484B2 (pt) |
BG (1) | BG64540B1 (pt) |
BR (1) | BR9909872A (pt) |
CA (1) | CA2326339C (pt) |
CZ (1) | CZ301013B6 (pt) |
DE (1) | DE69934305T2 (pt) |
DK (1) | DK1069893T3 (pt) |
EA (1) | EA005524B1 (pt) |
ES (1) | ES2278441T3 (pt) |
GB (1) | GB2352972B (pt) |
HU (1) | HU229162B1 (pt) |
IL (1) | IL138416A (pt) |
NO (1) | NO329194B1 (pt) |
NZ (1) | NZ507203A (pt) |
PL (1) | PL192517B1 (pt) |
PT (1) | PT1069893E (pt) |
SI (1) | SI1069893T1 (pt) |
SK (1) | SK286160B6 (pt) |
TR (1) | TR200002837T2 (pt) |
TW (1) | TW552136B (pt) |
WO (1) | WO1999049854A2 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE312606T1 (de) | 1999-10-29 | 2005-12-15 | Orion Corp | Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock |
NZ535484A (en) * | 2002-04-08 | 2009-01-31 | Mgi Gp Inc | Pharmaceutical compositions containing fospropofol (O-phosphonooxymethylpropofol) and methods of administering same |
US7141597B2 (en) * | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
US20060058700A1 (en) * | 2004-08-26 | 2006-03-16 | Marro Dominic P | Patient sedation monitor |
WO2008036858A2 (en) | 2006-09-20 | 2008-03-27 | The Board Of Regents Of The University Of Texas System | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
EP3581169A1 (en) | 2008-01-22 | 2019-12-18 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
EP2429521B1 (en) * | 2009-05-15 | 2017-10-18 | Recro Pharma, Inc. | Sublingual dexmedetomidine compositions and methods of use thereof |
DE102009050016A1 (de) | 2009-05-27 | 2011-05-05 | Modine Manufacturing Co., Racine | Wärmeübertragereinheit |
US20130096170A1 (en) * | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
US9795559B2 (en) | 2011-12-11 | 2017-10-24 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
US8242158B1 (en) * | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
JP5921928B2 (ja) * | 2012-03-28 | 2016-05-24 | テルモ株式会社 | 既希釈デクスメデトミジン製剤 |
BR112015008459B1 (pt) * | 2012-10-15 | 2020-11-10 | Orion Corporation | uso de dexmedetomidina, medetomidina ou um sal farmaceuticamente aceitável destas para a fabricação de um medicamento para aliviar a aversão ao ruído em um animal |
WO2015011177A1 (en) | 2013-07-24 | 2015-01-29 | I-Tech Ab | Use of the enantiomer levomedetomidine as inhibitor for marine biofouling of surfaces |
RU2648449C2 (ru) | 2013-10-07 | 2018-03-26 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина |
TWI629066B (zh) * | 2013-10-07 | 2018-07-11 | 帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
RU2018105761A (ru) * | 2013-10-07 | 2019-02-26 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Устройства для трансдермальной доставки дексмедетомидина и способы их применения |
CN113975273B (zh) * | 2020-07-27 | 2023-07-11 | 宜昌人福药业有限责任公司 | 一种抗焦虑用纳米混悬鼻腔喷雾剂及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
FI844786A0 (fi) * | 1984-12-04 | 1984-12-04 | Farmos Oy | Terapeutiskt utnyttjbar foerening. |
GB2206880B (en) * | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
US5344840A (en) * | 1988-02-29 | 1994-09-06 | Orion-Yhtyma Oy | 4-substituted imidazole derivatives useful in perioperative care |
GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
US5217718A (en) * | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
GB2281206A (en) * | 1993-08-25 | 1995-03-01 | Orion Yhtymae Oy | Use of dexmedetomidine |
-
1999
- 1999-03-30 AR ARP990101414A patent/AR015744A1/es unknown
- 1999-03-31 AT AT99913332T patent/ATE347359T1/de active
- 1999-03-31 IL IL13841699A patent/IL138416A/xx not_active IP Right Cessation
- 1999-03-31 BR BRPI9909872-5A patent/BR9909872A/pt not_active Application Discontinuation
- 1999-03-31 EP EP99913332A patent/EP1069893B1/en not_active Expired - Lifetime
- 1999-03-31 ES ES99913332T patent/ES2278441T3/es not_active Expired - Lifetime
- 1999-03-31 GB GB0024932A patent/GB2352972B/en not_active Expired - Lifetime
- 1999-03-31 DK DK99913332T patent/DK1069893T3/da active
- 1999-03-31 PL PL343553A patent/PL192517B1/pl unknown
- 1999-03-31 CZ CZ20003484A patent/CZ301013B6/cs not_active IP Right Cessation
- 1999-03-31 JP JP2000540820A patent/JP4606581B2/ja not_active Expired - Lifetime
- 1999-03-31 NZ NZ507203A patent/NZ507203A/xx not_active IP Right Cessation
- 1999-03-31 PT PT99913332T patent/PT1069893E/pt unknown
- 1999-03-31 EA EA200001010A patent/EA005524B1/ru not_active IP Right Cessation
- 1999-03-31 TR TR2000/02837T patent/TR200002837T2/xx unknown
- 1999-03-31 CN CNB998046272A patent/CN1168441C/zh not_active Ceased
- 1999-03-31 SK SK1436-2000A patent/SK286160B6/sk not_active IP Right Cessation
- 1999-03-31 WO PCT/FI1999/000266 patent/WO1999049854A2/en active IP Right Grant
- 1999-03-31 CA CA002326339A patent/CA2326339C/en not_active Expired - Lifetime
- 1999-03-31 SI SI9930941T patent/SI1069893T1/sl unknown
- 1999-03-31 KR KR1020007010991A patent/KR20010034728A/ko not_active Application Discontinuation
- 1999-03-31 DE DE69934305T patent/DE69934305T2/de not_active Expired - Lifetime
- 1999-03-31 AU AU31494/99A patent/AU754484B2/en not_active Expired
- 1999-03-31 HU HU0101498A patent/HU229162B1/hu unknown
- 1999-04-01 TW TW088105188A patent/TW552136B/zh not_active IP Right Cessation
-
2000
- 2000-09-26 BG BG104797A patent/BG64540B1/bg unknown
- 2000-09-29 NO NO20004931A patent/NO329194B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9909872A (pt) | uso de dexmedetomidina para uma unidade de sedação de proteção intensiva | |
BRPI0519195A2 (pt) | composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal | |
BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
DE69939651D1 (de) | Behandlung hyperproliferativer erkrankungen | |
BR0315166A (pt) | Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
BR0017075A (pt) | Derivados de piridopirimidinona para tratamento de doença neurodegenerativa | |
ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
AUPR177300A0 (en) | Therapeutic methods | |
SE9803710D0 (sv) | Use of certain drugs for treating nerve root injury | |
BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
DE59401401D1 (de) | Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit | |
BRPI0507657A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
EP1348466A3 (en) | Method for treating pain with adenosine-tetraphosphates | |
BRPI0508333A (pt) | uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit | |
BRPI0416882A (pt) | composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
EA200500941A1 (ru) | Средство для лечения болезней суставов | |
BR0110913A (pt) | Método de administrar um bisfosfonato | |
BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
BRPI0409413A (pt) | composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável | |
BRPI0408500A (pt) | tratamento do diabetes do tipo 1 com inibidores de pde5 | |
PT986393E (pt) | Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA A INT.CI 7: A61K 31/4174; A61P 25/20 Ipc: A61K 31/4174 (2008.04), A61P 25/20 (2008.04) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O , 13 E 10 ( VIII ) DA LPI. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |